{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T10:36:05Z","timestamp":1782988565238,"version":"3.54.5"},"reference-count":37,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82302314"],"award-info":[{"award-number":["82302314"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271938"],"award-info":[{"award-number":["82271938"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2022A1515110792"],"award-info":[{"award-number":["2022A1515110792"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2023A1515220097"],"award-info":[{"award-number":["2023A1515220097"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2024A1515010653"],"award-info":[{"award-number":["2024A1515010653"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science and technology Projects in Guangzhou","award":["2023A04J1275"],"award-info":[{"award-number":["2023A04J1275"]}]},{"name":"Science and technology Projects in Guangzhou","award":["2024A03J1030"],"award-info":[{"award-number":["2024A03J1030"]}]},{"name":"Science and technology Projects in Guangzhou","award":["2025A03J4162"],"award-info":[{"award-number":["2025A03J4162"]}]},{"name":"Science and technology Projects in Guangzhou","award":["2025A03J4163"],"award-info":[{"award-number":["2025A03J4163"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>This study aimed to develop machine learning models based on conventional MRI features to classify HER2 expression levels in invasive breast cancer and explore their association with disease-free survival (DFS). A total of 678 patients from two centers were included, with Center 1 divided into training and internal test sets and Center 2 serving as an external test set. Random Forest models were trained to distinguish HER2-positive vs. HER2-negative (Task 1) and HER2-low vs. HER2-zero tumors (Task 2) using BI-RADS\u2013based MRI features. SHapley Additive exPlanations were applied to rank feature importance, assist feature selection, and enhance model interpretability. DFS was analyzed using Kaplan\u2013Meier curves and log-rank tests. In Task 1, key features included tumor size, axillary lymph nodes, fibroglandular tissue, peritumoral edema, and multifocal, achieving AUCs of 0.75 and 0.73 in the internal and external test sets, respectively. In Task 2, tumor size, peritumoral edema, and multifocal yielded AUCs of 0.73 and 0.72, respectively. Higher task-specific model scores were associated with shorter DFS in Task 1 (p = 0.037) and longer DFS in Task 2 (p = 0.046). MRI-based machine learning models can noninvasively stratify HER2 expression levels, with potential for prognostic stratification and clinical application.<\/jats:p>","DOI":"10.3390\/curroncol33010053","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:27:53Z","timestamp":1768570073000},"page":"53","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Machine Learning Model Based on Multiparametric MRI for Distinguishing HER2 Expression Level in Breast Cancer"],"prefix":"10.3390","volume":"33","author":[{"given":"Yongxin","family":"Chen","sequence":"first","affiliation":[{"name":"The First School of Clinical Medicine, Jinan University, Guangzhou 510632, China"},{"name":"Department of Radiology, Guangzhou First People\u2019s Hospital, South China University of Technology, Guangzhou 510180, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Guangzhou First People\u2019s Hospital, South China University of Technology, Guangzhou 510180, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Guangzhou First People\u2019s Hospital, South China University of Technology, Guangzhou 510180, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingcong","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiology, Guangzhou First People\u2019s Hospital, South China University of Technology, Guangzhou 510180, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Guangzhou First People\u2019s Hospital, South China University of Technology, Guangzhou 510180, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Radiology, Guangzhou First People\u2019s Hospital, South China University of Technology, Guangzhou 510180, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Radiology, Guangzhou First People\u2019s Hospital, South China University of Technology, Guangzhou 510180, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinqing","family":"Jiang","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Jinan University, Guangzhou 510632, China"},{"name":"Department of Radiology, Guangzhou First People\u2019s Hospital, South China University of Technology, Guangzhou 510180, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"102033","DOI":"10.1016\/j.ctrv.2020.102033","article-title":"HER2-positive advanced breast cancer treatment in 2020","volume":"88","author":"Cesca","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cai2.46","article-title":"Advances in medical treatment of breast cancer in 2022","volume":"2","author":"Zhai","year":"2023","journal-title":"Cancer Innov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1200\/JCO.19.02318","article-title":"Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients with HER2-Low-Expressing Advanced Breast Cancer: Results from a Phase Ib Study","volume":"38","author":"Modi","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.7326\/0003-4819-152-1-201001050-00190","article-title":"Systematic review: Comparative effectiveness of core-needle and open surgical biopsy to diagnose breast lesions","volume":"152","author":"Bruening","year":"2010","journal-title":"Ann. Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Lu, Y., Zhu, S., Tong, Y., Fei, X., Jiang, W., Shen, K., and Chen, X. (2022). HER2-Low Status Is Not Accurate in Breast Cancer Core Needle Biopsy Samples: An Analysis of 5610 Consecutive Patients. Cancers, 14.","DOI":"10.3390\/cancers14246200"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s12282-024-01585-3","article-title":"Concordance of HER2 status between core needle biopsy and surgical resection specimens of breast cancer: An analysis focusing on the HER2-low status","volume":"31","author":"Na","year":"2024","journal-title":"Breast Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1007\/s00330-024-10641-7","article-title":"Discrimination between HER2-overexpressing, -low-expressing, and -zero-expressing statuses in breast cancer using multiparametric MRI-based radiomics","volume":"34","author":"Zheng","year":"2024","journal-title":"Eur. Radiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.acra.2024.10.033","article-title":"Early and noninvasive prediction of response to neoadjuvant therapy for breast cancer via longitudinal ultrasound and MR deep learning: A multicentre study","volume":"32","author":"Zeng","year":"2025","journal-title":"Acad. Radiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00330-023-09990-6","article-title":"Noninvasive identification of HER2-low-positive status by MRI-based deep learning radiomics predicts the disease-free survival of patients with breast cancer","volume":"34","author":"Guo","year":"2024","journal-title":"Eur. Radiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e222646","DOI":"10.1148\/radiol.222646","article-title":"Multiparametric MRI and Radiomics for the Prediction of HER2-Zero, -Low, and -Positive Breast Cancers","volume":"308","author":"Ramtohul","year":"2023","journal-title":"Radiology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/jmri.28628","article-title":"Potential Antihuman Epidermal Growth Factor Receptor 2 Target Therapy Beneficiaries: The Role of MRI-Based Radiomics in Distinguishing Human Epidermal Growth Factor Receptor 2-Low Status of Breast Cancer","volume":"58","author":"Bian","year":"2023","journal-title":"J. Magn. Reson. Imaging JMRI"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e2431717","DOI":"10.2214\/AJR.24.31717","article-title":"Multiparametric MRI Radiomics with Machine Learning for Differentiating HER2-Zero, -Low, and -Positive Breast Cancer: Model Development, Testing, and Interpretability Analysis","volume":"224","author":"Chen","year":"2025","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1007\/s00330-023-10198-x","article-title":"Discrimination between human epidermal growth factor receptor 2 (HER2)-low-expressing and HER2-overexpressing breast cancers: A comparative study of four MRI diffusion models","volume":"34","author":"Mao","year":"2024","journal-title":"Eur. Radiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.acra.2024.07.048","article-title":"A Comprehensive Model Outperformed the Single Radiomics Model in Noninvasively Predicting the HER2 Status in Patients with Breast Cancer","volume":"32","author":"Liu","year":"2025","journal-title":"Acad. Radiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100592","DOI":"10.1016\/j.ejro.2024.100592","article-title":"MRI-based machine learning radiomics for prediction of HER2 expression status in breast invasive ductal carcinoma","volume":"13","author":"Luo","year":"2024","journal-title":"Eur. J. Radiol. Open"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"C\u00e8, M., Chiriac, M.D., Cozzi, A., Macr\u00ec, L., Rabaiotti, F.L., Irmici, G., Fazzini, D., Carrafiello, G., and Cellina, M. (2024). Decoding Radiomics: A Step-by-Step Guide to Machine Learning Workflow in Hand-Crafted and Deep Learning Radiomics Studies. Diagnostics, 14.","DOI":"10.3390\/diagnostics14222473"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1148\/radiol.2018181352","article-title":"Radiomic versus Convolutional Neural Networks Analysis for Classification of Contrast-enhancing Lesions at Multiparametric Breast MRI","volume":"290","author":"Truhn","year":"2019","journal-title":"Radiology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/jmri.29447","article-title":"Preoperative Differentiation of HER2-Zero and HER2-Low from HER2-Positive Invasive Ductal Breast Cancers Using BI-RADS MRI Features and Machine Learning Modeling","volume":"61","author":"Zhou","year":"2025","journal-title":"J. Magn. Reson. Imaging JMRI"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Elshawi, R., Al-Mallah, M.H., and Sakr, S. (2019). On the interpretability of machine learning-based model for predicting hypertension. BMC Med. Inform. Decis. Mak., 19.","DOI":"10.1186\/s12911-019-0874-0"},{"key":"ref_22","first-page":"204","article-title":"Opening the Black Box: The Promise and Limitations of Explainable Machine Learning in Cardiology","volume":"38","author":"Petch","year":"2022","journal-title":"Can. J. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/biof.1995","article-title":"Breast cancer diagnosis and management guided by data augmentation, utilizing an integrated framework of SHAP and random augmentation","volume":"50","author":"Ejiyi","year":"2024","journal-title":"BioFactors"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"102409","DOI":"10.1016\/j.eclinm.2023.102409","article-title":"Identification and validation of an explainable prediction model of acute kidney injury with prognostic implications in critically ill children: A prospective multicenter cohort study","volume":"68","author":"Hu","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1007\/s00330-021-08271-4","article-title":"Predicting the molecular subtype of breast cancer and identifying interpretable imaging features using machine learning algorithms","volume":"32","author":"Ma","year":"2022","journal-title":"Eur. Radiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.diii.2024.01.004","article-title":"Multiparametric MRI model to predict molecular subtypes of breast cancer using Shapley additive explanations interpretability analysis","volume":"105","author":"Huang","year":"2024","journal-title":"Diagn. Interv. Imaging"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s00330-015-3935-5","article-title":"Which factors influence MRI-pathology concordance of tumour size measurements in breast cancer?","volume":"26","author":"Rominger","year":"2016","journal-title":"Eur. Radiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1148\/radiol.2020192534","article-title":"Axillary Nodal Evaluation in Breast Cancer: State of the Art","volume":"295","author":"Chang","year":"2020","journal-title":"Radiology"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"\u015een, G.A., Ayd\u0131n, E., Guliyev, M., \u00d6zta\u015f, N., De\u011ferli, E., Demirci, N.S., Turna, Z.H., and Demirelli, F.H. (2024). The impact of HER2-low status on pathological complete response and disease-free survival in early-stage breast cancer. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-13064-1"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/jech.50.6.674","article-title":"Reliability of data from proxy respondents in an international case-control study of cardiovascular disease and oral contraceptives. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception","volume":"50","author":"Poulter","year":"1996","journal-title":"J. Epidemiol. Community Health"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e2330603","DOI":"10.2214\/AJR.23.30603","article-title":"Development and Validation of MRI Radiomics Models to Differentiate HER2-Zero, -Low, and -Positive Breast Cancer","volume":"222","author":"Peng","year":"2024","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"106955","DOI":"10.1016\/j.crad.2025.106955","article-title":"Combining conventional magnetic resonance imaging (MRI) parameters with clinicopathologic data for differentiation of the three-tiered human epidermal growth factor receptor 2 (HER2) status in breast cancer","volume":"86","author":"Liu","year":"2025","journal-title":"Clin. Radiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"104571","DOI":"10.1016\/j.ebiom.2023.104571","article-title":"Comprehensive characterization of HER2-low breast cancers: Implications in prognosis and treatment","volume":"91","author":"Li","year":"2023","journal-title":"eBioMedicine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"197","DOI":"10.21037\/gs-22-747","article-title":"Bioinformatics combined with clinical data to analyze clinical characteristics and prognosis in patients with HER2 low expression breast cancer","volume":"12","author":"Chen","year":"2023","journal-title":"Gland. Surg."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"npj Breast Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","article-title":"Clinical and molecular characteristics of HER2-low-positive breast cancer: Pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials","volume":"22","author":"Denkert","year":"2021","journal-title":"Lancet Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/1\/53\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T05:27:40Z","timestamp":1768714060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/1\/53"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["curroncol33010053"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33010053","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]}}}